A novel heparan sulfate glycosaminoglycan mimetic product for local application to promote wound healing (CACIPLIQ) has recently become available. It is a biophysical therapeutic product comprising a polysaccharide as an innovative biomaterial to accomplish mechanical tissue engineering and skin regeneration in the site of ulceration. We present a series of 12 patients with type 2 diabetes (4 men and 8 women; age 53-87 years; diabetes duration 8-25 years) having chronic resistance to therapy for foot and lower extremity ulcerations. CACIPLIQ was locally applied twice per week after careful debridement. Complete ulcer healing was accomplished in all patients after a mean treatment duration of 4.92 months (range = 2-12 months). The product was very well tolerated. In conclusion, these results, although preliminary, are encouraging and suggest adequate efficacy and safety of the new product in difficult-to-heal foot and lower extremity ulcerations in type 2 diabetes.
PapanasNMaltezosEEdmondsM. Salvation of the diabetic foot: still a quest for the Holy Grail?Vasa. 2011;40:267-269.
2.
EdmondsM. Double trouble: infection and ischemia in the diabetic foot. Int J Low Extrem Wounds. 2009;8:62-63.
3.
PapanasNManiR. Advances in infections and wound healing for the diabetic foot: the die is cast. Int J Low Extrem Wounds. 2013;12:83-86.
4.
PapanasNLazaridesMK. Diabetic foot amputations in Greece: where do we go from here?Int J Low Extrem Wounds. 2011;10:4-5.
5.
SkoutasDPapanasNGeorgiadisGSRisk factors for ipsilateral reamputation in patients with diabetic foot lesions. Int J Low Extrem Wounds. 2009;8:69-74.
6.
PapanasNMaltezosE. Glycated hemoglobin as a risk factor for lower extremity amputations in diabetes: “success is counted sweetest.”Int J Low Extrem Wounds. 2015;14:106-107.
7.
PapanasNEleftheriadouITentolourisNMaltezosE. Advances in the topical treatment of diabetic foot ulcers. Curr Diabetes Rev. 2012;8:209-218.
8.
KakagiaDDKazakosKJXarchasKC. Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. J Diabetes Complications. 2007;21:387-391.
9.
PapanasNMaltezosE. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?Int J Low Extrem Wounds. 2007;6:37-53.
10.
PapanasNMaltezosE. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf. 2010;33:455-461.
11.
TiakaEKPapanasNManolakisACMaltezosE. The role of hyperbaric oxygen in the treatment of diabetic foot ulcers. Angiology. 2012;63:302-314.
12.
GeorgakarakosECharalampidisDKakagiaDGeorgiadisGSLazaridesMKPapanasN. Current achievements with topical negative pressure to improve wound healing in dehiscent ischemic stumps of diabetic patients: a case series. Int J Low Extrem Wounds. 2013;12:138-145.
13.
PanagopoulosPDrososGMaltezosEPapanasN. Local antibiotic delivery systems in diabetic foot osteomyelitis: time for one step beyond?Int J Low Extrem Wounds. 2015;14:87-91.
14.
MikroulisDPapanasNMaltezosEBougioukasG. Angiogenic growth factors in the treatment of peripheral arterial disease. Curr Vasc Pharmacol. 2007;5:195-209.
15.
GeorgakarakosEPapanasNPapadakiEGeorgiadisGSMaltezosELazaridesMK. Endovascular treatment of critical ischemia in the diabetic foot: new thresholds, new anatomies. Angiology. 2013;64:583-591.
16.
Aragón-SánchezJ. Seminar review: A review of the basis of surgical treatment of diabetic foot infections. Int J Low Extrem Wounds. 2011;10:33-65.
17.
Aragón-SánchezJLázaro-MartínezJLHernández-HerreroC. Surgical treatment of limb- and life-threatening infections in the feet of patients with diabetes and at least one palpable pedal pulse: successes and lessons learnt. Int J Low Extrem Wounds. 2011;10:207-213.
18.
Aragón-SánchezJLázaro-MartínezJLMolinés-BarrosoR. Revision surgery for diabetic foot infections: giving another chance to the patient. Int J Low Extrem Wounds. 2013;12:146-151.
19.
TongMTukBHekkingIMVermeijMBarritaultDvan NeckJW. Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120. Wound Repair Regen. 2009;17:840-852.
20.
TongMTukBHekkingIM. Heparan sulfate glycosaminoglycan mimetic improves pressure ulcer healing in a rat model of cutaneous ischemia-reperfusion injury. Wound Repair Regen. 2011;19:505-514.
21.
TongMTukBShangP. Diabetes-impaired wound healing is improved by matrix therapy with heparan sulfate glycosaminoglycan mimetic OTR4120 in rats. Diabetes. 2012;61:2633-2641.
22.
DesgrangesPLouissaintTAllaireE. First clinical pilot study on critical ischemic leg ulcers with Matrix Therapy Regenerating Agent (RGTA) technology. J Wound Technol. 2011;13:1-6.
23.
PrompersLHuijbertsMApelqvistJ. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50:18-25.
24.
DemetriouMPapanasNPanopoulouMPapatheodorouKBounovasAMaltezosE. Tissue and swab culture in diabetic foot infections: neuropathic versus neuroischemic ulcers. Int J Low Extrem Wounds. 2013;12:87-93.
25.
GouveriEPapanasN. Charcot osteoarthropathy in diabetes: a brief review with an emphasis on clinical practice. World J Diabetes. 2011;2:59-65.
26.
YoungMJBoultonAJMacLeodAFWilliamsDRSonksenPH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150-154.
27.
GeorgakarakosEPapadakiEVamvakerouV. Training to measure ankle-brachial index at the undergraduate level: can it be successful?Int J Low Extrem Wounds. 2013;12:167-171.
28.
PapanasNSymeonidisGMavridisG. Ankle-brachial index: a surrogate marker of microvascular complications in type 2 diabetes mellitus. Int Angiol. 2007;26:253-257.
29.
KunduBKunduSC. Silk sericin/polyacrylamide in situ forming hydrogels for dermal reconstruction. Biomaterials. 2012;33:7456-7467.
30.
FrancoDMildFKlingaufM. Accelerated endothelial wound healing on microstructured substrates under flow. Biomaterials. 2013;34:1488-1497.
31.
DemetzosC. Biophysics and thermodynamics: the scientific building blocks of bio-inspired drug delivery nano systems. AAPS PharmSciTech. 2015;16:491-495.
